ImmunoForge Co., Ltd.
PrivateLast Round
Series C
Oct 1, 2025
Est. Valuation
$75.8M
Total Funding Raised
$38.58M
Company Overview
ImmunoForge Co., Ltd. operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series C round in October 2025.
ImmunoForge Co., Ltd. is a biotechnology company that develops therapies for treating cancer and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoForge Co., Ltd. Comparables
Compare ImmunoForge Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XL-protein | 76% | |
| Hanmi Pharm Co Ltd | 74% | |
| Sanofi | 71% |
For institutional investors. Book with your work email.
ImmunoForge Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 1, 2025 | ||||
| Series B | Sep 1, 2021 | ||||
| Series A Extension | Aug 1, 2020 | ||||
| Series A | Feb 1, 2019 | ||||
| Seed | Dec 1, 2017 |
For institutional investors. Book with your work email.
ImmunoForge Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BNH INVESTMENT | Series B, Series A |
| Smilegate Investment | Series A |
| Company K Partners | Series C, Series B, Series A |
| KB Securities | Series B |
| Kiwoom Investment | Series B |
| Korea Omega Investment Corp | Series A |
| Korea Development Bank | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2025
Raised $9.5M from Company K Partners, LB Investment, and Korea Development Bank.
- Sep 1, 2021
$19M round with participation from KB Securities and Kiwoom Investment.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardOct 22, 2026
ImmunoForge Inc.'s LMT platform receives 1st Place at the Novo Nordisk Partnering Day.
- attends_eventOct 22, 2026
ImmunoForge Inc. participates in BIO-Europe 2026 in Germany from Nov 9th–11th '26, showcasing proprietary platform technologies and next-generation oncology and Phase 2 clinical pipelines.
- receives_financingAug 24, 2026
ImmunoForge Inc. is selected for the 2026 Global TIPS R&D program and is set to receive $3.58M in government funding over four years to develop its blood-brain-barrier-penetrating hybrid LNP platform in South Korea on Aug 24th '26.
- attends_eventAug 24, 2026
ImmunoForge Inc. wins first place in the Open Innovation contest hosted by Novo Nordisk, highlighting recognition of its technological capabilities.
For institutional investors. Book with your work email.
ImmunoForge Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunoForge Co., Ltd.'s valuation, stock price, and market status.
Is ImmunoForge Co., Ltd. a public or private company?
ImmunoForge Co., Ltd. is a private company.
What is the current stock price of ImmunoForge Co., Ltd.?
ImmunoForge Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks ImmunoForge Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunoForge Co., Ltd. worth (valuation)?
ImmunoForge Co., Ltd.'s valuation is estimated at $75.8M based on funding round data.
Can I buy ImmunoForge Co., Ltd. stock?
ImmunoForge Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunoForge Co., Ltd.'s last funding round?
ImmunoForge Co., Ltd.'s most recent funding round was Series C on October 1, 2025.
Who are the main investors in ImmunoForge Co., Ltd.?
Key investors in ImmunoForge Co., Ltd. include BNH INVESTMENT, Smilegate Investment, Company K Partners, KB Securities, Kiwoom Investment.
Will ImmunoForge Co., Ltd. IPO soon?
No public IPO plans have been announced for ImmunoForge Co., Ltd..
How can I track ImmunoForge Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in ImmunoForge Co., Ltd.'s shares on secondary markets.